Monte Rosa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
Cons olidated statements of cash flows
| Year endedDecember 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| Cash flows from operating activities: | ||
| Net loss | $(135,352) | $(108,501) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 16,669 | 11,664 |
| Depreciation | 6,222 | 3,745 |
| Noncash lease expense | — | 4,814 |
| Net accretion of discounts/premiums on marketable securities | (3,914) | (1,945) |
| Loss on sale of marketable securities | 131 | — |
| Gain on disposal of property and equipment | (24) | (109) |
| Changes in operating assets and liabilities | ||
| Other receivables | 1,897 | (187) |
| Prepaid expenses and other current assets | 1,077 | (2,127) |
| Accounts payable | 5,758 | (744) |
| Accrued expenses and other current liabilities | 3,557 | 1,031 |
| Defined benefit plan liability | (188) | 74 |
| Right-of-use assets and operating lease liabilities | 10,365 | (181) |
| Deferred revenue | 50,000 | — |
| Net cash used in operating activities | $(43,802) | $(92,466) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (19,041) | (12,911) |
| Proceeds from sale of property and equipment | 62 | 109 |
| Purchases of marketable securities | (103,151) | (384,417) |
| Proceeds from sale of marketable securities | 45,631 | — |
| Proceeds from maturities of marketable securities | 165,300 | 178,000 |
| Net cash provided by (used in) investing activities | $88,801 | $(219,219) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of underwriting discount of $620 | — | 20,055 |
| Proceeds from issuance of pre-funded warrants | 25,000 | — |
| Proceeds from exercise of employee stock options | 2,030 | 439 |
| Proceeds from employee stock purchase plan | 578 | 336 |
| Payment of common stock issuance costs | — | (364) |
| Payment of pre-funded warrant issuance costs | (116) | — |
| Net cash provided by financing activities | $27,492 | $20,466 |
| Net decrease in cash, cash equivalents and restricted cash | $72,491 | $(291,219) |
| Cash, cash equivalents and restricted cash—beginning of period | 60,190 | 351,409 |
| Cash, cash equivalents and restricted cash—end of period | $132,681 | $60,190 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $128,101 | $54,912 |
| Restricted cash | 4,580 | 5,278 |
| Total cash, cash equivalents and restricted cash | $132,681 | $60,190 |
| Supplemental disclosure of noncash items | ||
| Reduction of right-of-use assets for lease incentives receivable | $5,253 | $7,469 |
| Purchases of property and equipment in accounts payable and accrued expenses | $237 | $6,240 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.